243 related articles for article (PubMed ID: 38169551)
1. Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma.
Jeng LB; Wang J; Teng CF
J Cancer; 2024; 15(2):484-493. PubMed ID: 38169551
[TBL] [Abstract][Full Text] [Related]
2. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.
Sharafi F; Hasani SA; Alesaeidi S; Kahrizi MS; Adili A; Ghoreishizadeh S; Shomali N; Tamjidifar R; Aslaminabad R; Akbari M
Cancer Cell Int; 2022 Aug; 22(1):269. PubMed ID: 35999569
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Dong Y; Wong JSL; Sugimura R; Lam KO; Li B; Kwok GGW; Leung R; Chiu JWY; Cheung TT; Yau T
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919570
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.
Liu HT; Jiang MJ; Deng ZJ; Li L; Huang JL; Liu ZX; Li LQ; Zhong JH
Front Oncol; 2021; 11():737497. PubMed ID: 34745958
[TBL] [Abstract][Full Text] [Related]
6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
7. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
Leone P; Solimando AG; Fasano R; Argentiero A; Malerba E; Buonavoglia A; Lupo LG; De Re V; Silvestris N; Racanelli V
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065489
[TBL] [Abstract][Full Text] [Related]
9. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
Peng X; Gong C; Zhang W; Zhou A
Front Oncol; 2022; 12():1091088. PubMed ID: 36727075
[TBL] [Abstract][Full Text] [Related]
10. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
11. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
[TBL] [Abstract][Full Text] [Related]
12. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
Federico P; Petrillo A; Giordano P; Bosso D; Fabbrocini A; Ottaviano M; Rosanova M; Silvestri A; Tufo A; Cozzolino A; Daniele B
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080958
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract][Full Text] [Related]
16. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
17. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
18. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
19. Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer.
Cho U; Im S; Park HS
J Pathol Transl Med; 2024 Mar; 58(2):49-58. PubMed ID: 38389279
[TBL] [Abstract][Full Text] [Related]
20. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
